IRIS
CICCARELLI, LEONARDINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.116
AS - Asia 2.699
EU - Europa 1.998
SA - Sud America 284
AF - Africa 63
Continente sconosciuto - Info sul continente non disponibili 4
OC - Oceania 4
Totale 8.168
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.046
CN - Cina 1.525
SG - Singapore 559
IE - Irlanda 516
UA - Ucraina 369
DE - Germania 273
FI - Finlandia 246
HK - Hong Kong 225
BR - Brasile 207
RU - Federazione Russa 184
VN - Vietnam 163
FR - Francia 104
SE - Svezia 102
IT - Italia 82
IN - India 63
GB - Regno Unito 58
CA - Canada 39
ZA - Sudafrica 33
IQ - Iraq 24
AR - Argentina 23
BD - Bangladesh 22
NL - Olanda 15
MX - Messico 14
TR - Turchia 14
EC - Ecuador 13
JO - Giordania 11
PL - Polonia 11
CL - Cile 10
PK - Pakistan 10
UZ - Uzbekistan 10
VE - Venezuela 10
JP - Giappone 9
SA - Arabia Saudita 9
LT - Lituania 8
MA - Marocco 8
PH - Filippine 8
BO - Bolivia 7
ES - Italia 7
CO - Colombia 6
ID - Indonesia 6
IR - Iran 6
MY - Malesia 6
EG - Egitto 5
NP - Nepal 5
AL - Albania 4
EU - Europa 4
KE - Kenya 4
NI - Nicaragua 4
PY - Paraguay 4
AE - Emirati Arabi Uniti 3
BE - Belgio 3
CR - Costa Rica 3
GE - Georgia 3
NZ - Nuova Zelanda 3
PA - Panama 3
TN - Tunisia 3
AT - Austria 2
AZ - Azerbaigian 2
BB - Barbados 2
CY - Cipro 2
DZ - Algeria 2
GR - Grecia 2
KG - Kirghizistan 2
KZ - Kazakistan 2
LU - Lussemburgo 2
OM - Oman 2
PE - Perù 2
PT - Portogallo 2
UG - Uganda 2
AD - Andorra 1
AO - Angola 1
AU - Australia 1
BN - Brunei Darussalam 1
CH - Svizzera 1
CI - Costa d'Avorio 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
GA - Gabon 1
HN - Honduras 1
HR - Croazia 1
IL - Israele 1
JM - Giamaica 1
KH - Cambogia 1
KR - Corea 1
LA - Repubblica Popolare Democratica del Laos 1
LC - Santa Lucia 1
LK - Sri Lanka 1
LS - Lesotho 1
MD - Moldavia 1
NG - Nigeria 1
RO - Romania 1
SI - Slovenia 1
SN - Senegal 1
SR - Suriname 1
SY - Repubblica araba siriana 1
TH - Thailandia 1
TT - Trinidad e Tobago 1
UY - Uruguay 1
Totale 8.168
Salva come PNG Salva come JPEG
Città #
Dublin 516
Jacksonville 480
Chandler 396
Nanjing 350
San Jose 317
Singapore 263
Beijing 229
Hong Kong 218
Ashburn 216
Dallas 211
Nanchang 156
Boardman 149
Shenyang 121
Princeton 107
Jiaxing 103
Wilmington 103
Changsha 100
Lawrence 95
Hebei 92
Medford 81
Lauterbourg 80
Tianjin 66
Los Angeles 61
Hangzhou 52
Ho Chi Minh City 44
Munich 39
Hanoi 38
Helsinki 38
Buffalo 37
Redondo Beach 35
New York 34
Johannesburg 31
Toronto 26
Seattle 25
Shanghai 25
Moscow 24
Norwalk 22
São Paulo 20
Frankfurt am Main 18
Turku 18
Orem 16
Santa Clara 15
Des Moines 14
Woodbridge 13
Fairfield 12
Milan 12
San Francisco 12
Jinan 11
Pune 11
Amman 10
Ann Arbor 10
Atlanta 10
Baghdad 10
Haiphong 9
Quito 9
Kunming 8
Poplar 8
Tokyo 8
Warsaw 8
Chennai 7
Dearborn 7
London 7
Tashkent 7
Belo Horizonte 6
Da Nang 6
Eindhoven 6
Lanzhou 6
Montreal 6
Rio de Janeiro 6
Verona 6
Brooklyn 5
Guangzhou 5
New Delhi 5
Ningbo 5
Rome 5
Taizhou 5
Washington 5
Amsterdam 4
Biên Hòa 4
Caracas 4
Casablanca 4
Halifax 4
Istanbul 4
Jeddah 4
Managua 4
Manchester 4
Nairobi 4
Orange 4
Porto Alegre 4
Stockholm 4
Tehran 4
Zhengzhou 4
Boston 3
Brasília 3
Brussels 3
Bắc Giang 3
Bắc Ninh 3
Bến Tre 3
Campinas 3
Can Tho 3
Totale 5.431
Salva come PNG Salva come JPEG
Nome #
Association between low-molecular weight apolipoprotein(a) isoforms and obesity in Italian women 129
Confronto tra nateglinide più metformina rispetto a glibenclamide più metformina sul metabolismo glucidico nei pazienti diabetici di tipo 2: studio ad 1 anno 128
Confronto tra pioglitazone e rosiglitazone sul metabolismo glucidico e lipidico nei soggetti diabetici di tipo 2 in terapia con metformina 126
Comparison between diet, orlistat and fluvastatin in obese patients with mild hypertension and hypercholesterolemia 125
Atorvastatin-amlodipine combination and fibrinolytic balance in hypertensive hypercholesterolemic insulin-resistent patients 125
Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double-blind, clinical trial 123
Azione della moxonidina sul metabolismo glucidico e lipidico negli ipertesi con sindrome metabolica 123
Confronto tra dieta, orlistat e fluvastatina in soggetti obesi, con ipertensione arteriosa lieve e ipercolesterolemia 122
Effetti di pioglitazone e rosiglitazone nei pazienti con diabete di tipo 2 e sindrome metabolica trattati con metformina 119
Actions of glimepiride plus metformin compared to rosiglitazone plus metformin on glucose metabolism, fibrinolytic, and coagulation measurements in Type 2 diabetic patients. 119
Comparison between orlistat and sibutramine in obese patients with mild hypertension 117
Effetti metabolici di telmisartan e irbesartan nei pazienti diabetici di tipo 2 con sindrome metabolica trattati con rosiglitazone 115
Comparison between exenatide and glimepiride on metabolic control and on insulin resistance in type 2 diabetic patients with metformin therapy 110
Comparison between glimepiride plus pioglitazone vs. glimepiride plus rosiglitazone on glucose metabolism and on lipid, lipoprotein and apolipoprotein fractions in type 2 diabetic patients 110
Comparison between fosinopril and eprosartan on lipid profile and Lp(a) in normotensive, type 2 diabetic subjects, with microalbuminuria 106
Changes during glimepiride plus rosiglitazone vs glibenclamide plus rosiglitazone treatment on glucose metabolism and lipoprotein (a) in Type 2 diabetic patients. 105
Azione della moxonidina sul metabolismo glucidico e lipidico negli ipertesi con sindrome metabolica 105
The efficacy and safety of pioglitazone or rosiglitazone added onto metformin in type 2 diabetes patients with metabolic syndrome 105
Effect of amlodipine-atorvastatin combination on fibrinolysis in hypertensive hypercholesterolemic insulin-resistant patients 105
Metalloproteasi-2, metalloproteasi-9 ed inibitore tissutale delle metalloproteasi-1 in pazienti ipertesi 104
Doxazosin improves blood pressure and metabolic parameters in impaired glucose tolerance patients in therapy with acarbose 104
Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients 103
High Lp(a) levels and atherogenic isoforms in patients with acute coronary sindrome 102
Effects of rosiglitazone alone and in association with simvastatin on lipid and lipoprotein parameters in patients with metabolic syndrome 101
Effetti dell'associazione tra pioglitazone e sibutramina sul metabolismo glucidico e lipidico nei soggetti obesi diabetici di tipo 2 101
Le metalloprotesi -2 e -9 e i loro inibitori tissutali -1 e -2 nei soggetti sani e nei soggetti con diabete di tipo 2 100
Effetti metabolici di telmisartan e irbesartan nei apzienti diabetici di tipo 2 con sindrome metabolica trattati con rosiglitazone 97
Efficacy of fluvastatin together with fenofibrate in hypercholesterolemic type 2 diabetic subjects compared to monotherapy. 97
MMP-2, -9 and TIMP-1 in patients with hypertension before and after doxazosin therapy 96
Comparison between repaglinide plus metformin vs glimepiride plus metformin on glucose metabolism, fibrinolytic, and coagulation measurements in Type 2 diabetic patients: a 1 year 95
The efficacy and safety of pioglitazone or rosiglitazone added onto metformin on diabetic dyslipidemia 93
La doxazosina migliora i parametri pressori e l'assetto metabolico nei soggetti intolleranti al glucosio in terapia con acarbose 89
Comparison between glimepiride plus metformin vs rosiglitazone plus metformin on glucose metabolism and on blood pressure in Type 2 diabetic patients 89
Fosinopril vs eprosartan in normotensive, Type 2 diabetic patients, with microalbuminuria 88
Matrix metalloproteinases and tissue inhibitor metalloproteinases in hypertensive patients 88
Efficacia e sicurezza di pioglitazone o rosiglitazone in combinazione con metformina in pazienti con diabete di tipo 2 e sindrome metabolica 88
Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients 85
La terapia con rosiglitazone migliora i parametri di insulino-resisitenza nei pazienti diabetici in sovrappeso ed obesi intolleranti alla metformina 85
Efficacia di fluvastatina e fenofibrato in prevenzione secondaria rispetto alla monoterapia: studio ad 1 anno in pazienti diabetici di tipo 2, ipercolesterolemici 84
The efficacy and safety of pioglitazone or rosiglitazone added onto metformin on diabetic dyslipidemia 84
Metabolic and insulin resistance-related indices during pioglitazone and vildagliptin association versus glimepiride and vildagliptin association in type 2 diabetic patients 83
Matrix metalloproteinase-2,-9 and tissue inhibitor metalloproteinase-1,-2 in healthy and type 2 diabetic subjects 83
Efficacia e sicurezza del pioglitazone o rosiglitazone in combinazione con metformina su pazienti diabetici dislipidemici 82
Comparison between repaglinide plus metformin vs glimepiride plus metformin on glucose metabolism and lipoprotein (a) in type 2 diabetic patients: A 1-year study 82
Glycemic and extraglycemic effects of glimepiride plus pioglitazone vs glimepiride plus rosiglitazone therapy in Type 2 diabetic patients 81
Le metalloproteasi-2, -9 in differenti gruppi con e senza diabete 81
Matrix metalloproteinase 2 and 9 values in various groups with or without diabetes 81
Pioglitazone or rosiglitazone added onto metformin in type 2 diabetes with metabolic syndrome: effects on conventional and non-conventional cardiovascular risk factors 81
Matrix metalloproteinase-2, -9 and tissue inhibitor metalloproteinase-1, -2 in healthy and type 2 diabetic subjects 80
Comparison between Glimepiride Plus Rosiglitazone on Glucose Metabolism and on Lipid, Lipoprotein and Apolipoprotein Parameters in Type 2 Diabetic Patients 80
La doxazosina migliora i parametri pressori e l'assetto metabolico nei soggetti intolleranti al glucosio in terapia con acarbose 80
Matrix metalloproteinase 2 and 9 levels in diabetic and nondiabetic patients during and after acute coronary syndrome 79
Moxonidine action on glucose and lipid metabolism in hypertensive patients with metabolic syndrome 79
Matrix metalloproteinase 2 and 9 evaluation in different patient groups with or without diabetes 79
Rosiglitazone therapy improves insulin resistance parameters in overweight and obese diabetic patients intolerant to metformin 78
Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone: a double-blind, randomised clinical trial 78
Effects of exenatide compared to glibenclamide on glycemic control and on insulin resistance in type 2 diabetic patients with metformin therapy 78
Matrix metalloproteinases and tissue inhibitor metalloproteinases in hypertensive patients before and after antihypertensive therapy 78
Effetti metabolici di telmisartan e irbesartan nei pazienti diabetici di tipo 2 con sindrome metabolica trattati con rosiglitazone 78
Matrix metalloproteinase 2 and 9 values in various groups with or without diabetes 78
Matrix metalloproteinase-2, -9, and tissue inhibitor metalloproteinase-1 in patients with hypertension before and after doxazosin therapy 78
Effects of telmisartan compared to nifedipine in hypertensive, type 2 diabetic patients on glucose metabolism and lipid profile: a 1-year study 77
Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone 77
Rosiglitazone therapy improves insulin resistance parameters in overweight and obese diabetic patients intolerant to metformin 76
Valutazione endocrino-metabolica di una popolazione di pazienti obesi e confronto con soggetti normopeso 76
Matrix metalloproteinase-2, -9 and tissue inhibitor Metalloproteinase-1 in patients with hypertension 75
La doxazosina migliora i parametri pressori e l'assetto metabolico nei soggetti intolleranti al glucosio in terapia con acarbose 75
The efficacy and safety of pioglitazone or rosiglitazone added onto metformin in type 2 diabetes patients with metabolic syndrome 74
La sibutramina non modifica i parametri emodinamici bnegli obesi, diabetici di tipo 2 73
Valutazione delle metalloproteasi 2 e 9 in pazienti con o senza diabete durante sindrome coronarica acuta e dopo evento acuto 73
Efficacy of fluvastatin together with fenofibrate in secondary prevention compared to monotherapy in hypercholesterolemic, type 2 diabetic subjects: A 1-year study 72
Prevalenza di elevati livelli di Lp(a) e di isoforme aterogene in un gruppo di pazienti del Nord Italia con sindrome coronarica acuta 71
Fenofibrate and fluvastatin compared to monotherapy in hypercholesterolemic diabetic patients with coronary heart disease: a 1 year study 71
Terapia con telmisartan e irbesartan nei pazienti con diabete di tipo 2 trattati con rosiglitazone: effetti sull'insulino-resistenza, leptina e TNF-alfa 70
Pioglitazone or rosiglitazone added onto metformin in type 2 diabetes patients with metabolic syndrome: effects on conventional and non-conventional cardiovascular risk factors 70
Stress ossidativo e rischio vascolare. Quale ruolo per gli antiossidanti? 70
Matrix metalloproteinase-2,-9 and tissue inhibitor metalloproteinase-1,-2 in patients with acute coronary syndrome with or without diabetes during and after acute event 70
The efficacy and safety of pioglitazone or rosiglitazone added onto metformin on diabetic dyslipidemia 70
Pioglitazone and sitagliptin compared to pioglitazone and metfomin therapy on glycaemic control and on insulin resistance in type 2 diabetic patients 69
Il sistema di monitoraggio continuo della glicemia nei soggetti sani: risultato di uno studio pilota 69
Effetti di exenatide in combinazione con metformina sulla funzione beta-cellulare in pazienti affetti da diabete mellito di tipo 2 69
Variation in inflammatory markers and glycemic parameters after 12 months of exenatide plus metformin treatment compared with metformin alone: A randomized placebo-controlled trial 68
Pioglitazone o rosiglitazone in associazione con metformina nei pazienti con diabete mellito di tipo 2 e sindrome metabolica: effetto sui fattori di rischio cardiovascolare convenzionali e non convenzionali 67
Glycemic control and cardiovascular risk profile in patients with type 2 diabetes treated with repaglinide or metformin 66
Pioglitazone or rosiglitazone added onto metformin in type 2 diabetes patients with metabolic syndrome: effects on markers of cardiovascular disease 66
Le metalloproteasi-2, -9 nei pazienti diabetici con sindrome coronarica prima e dopo l'evento acuto 65
Effects of Telmisartan Compared to Nifedipine in Hypertensive, Type 2 Diabetic Patients on Glucose Metabolism and Lipid Profile: A 1-Year Study 65
The improvement of Insulin-Resistance with Rosiglitazone Plus Metformin Compared to Glimepiride Plus Metformin Lowers Blood Pressure Values in Type 2 Diabetic Patients 65
Valutazione delle metalloproteasi 2 e 9 in differenti gruppi di pazienti con o senza diabete 64
Exenatide plus metformin compared with metformin alone on β-cell function in patients with Type 2 diabetes 62
Effetti dell'associazione tra pioglitazone e sibutramina sul metabolsimo glucidico e lipidico nei soggettiobesi diabetici di tipo 2 61
Lipid and lipoprotein effects of rosiglitazone alone and in association with simvastatin in patients with metabolic syndrome 60
Effetti metabolici di telmisartan e irbesartan nei pazienti diabetici di tipo 2 con sindrome metabolica trattati con rosiglitazone 58
Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone 57
Effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with metformin 50
Totale 8.188
Salva come PNG Salva come JPEG
Categoria #
all - tutte 31.774
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 31.774
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021210 0 0 0 0 0 0 0 0 0 98 95 17
2021/2022350 0 0 18 1 1 0 4 23 12 2 69 220
2022/20231.329 121 105 2 67 129 139 0 86 602 7 47 24
2023/2024410 30 103 19 32 32 103 5 43 3 12 12 16
2024/20251.068 8 107 46 37 10 31 61 77 262 6 115 308
2025/20262.375 261 175 261 217 267 118 559 112 238 167 0 0
Totale 8.188